July analyst upgrades and competitor data momentum propel TRAX
- No new company announcement on July 27 but shares jump 33.39% premarket
- Builds on early-July read-through from Forte Biosciences positive CD122 Phase 1b data
- HC Wainwright raised PT to $44 in July citing validation for TRAX ANB033
- Barclays hiked target to $48 on July 21; Piper Sandler at $54 with Strong Buy consensus
- Anticipation grows for Q4 2026 ANB033 celiac disease Phase 1b topline results
- Stock up ~90-100% since April 2026 Nasdaq debut with $180M cash position
- Retail momentum and potential short squeeze in small-cap biotech amplify move
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.